Rituximab for treating inhibitors in people with inherited severe hemophilia.

BACKGROUND Hemophilia A and B are inherited coagulation disorders characterized by a reduced or absent level of factor VIII or factor IX respectively. The severe form is characterized by a factor level less than 0.01 international units (IU) per milliliter. The development of inhibitors in hemophilia is the main complication of treatment, because the presence of these antibodies, reduces or even nullifies the efficacy of replacement therapy, making it very difficult to control the bleeding. People with inhibitors continue to have significantly higher risks of morbidity and mortality, with considerable treatment costs. Given the wide 'off-label' use of rituximab for treating people with hemophilia and inhibitors, its efficacy and safety need to be evaluated. OBJECTIVES To assess the efficacy and safety of rituximab for treating inhibitors in people with inherited severe hemophilia A or B. SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register, complied from electronic database searches and handsearching of journals and conference abstract books. We searched the reference lists of relevant articles and reviews and also searched for ongoing or unpublished studies.Date of last search: 27 January 2015. SELECTION CRITERIA Randomized controlled trials and controlled clinical trials investigating the efficacy and safety of rituximab for treating inhibitors in people with hemophilia. DATA COLLECTION AND ANALYSIS No randomized controlled trials matching the selection criteria were eligible for inclusion. MAIN RESULTS No randomized controlled trials on rituximab for treating inhibitors in people with hemophilia were identified. AUTHORS' CONCLUSIONS We were unable to identify any relevant trials on the efficacy and safety of rituximab for treating inhibitors in people with hemophilia. The research evidence available is from case reports and case series. Randomized controlled trials are needed to evaluate the efficacy and safety of rituximab for this condition. However, prior to the publication of any possible future randomized controlled trials, meta-analysis of case reports and case series may provide some evidence.

[1]  C. Santoro,et al.  Rituximab for treating inhibitors in people with inherited severe hemophilia. , 2017, The Cochrane database of systematic reviews.

[2]  Kunihiko Kobayashi,et al.  Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor. , 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  C. Santoro,et al.  Rituximab for treating inhibitors in children with hemophilia , 2013 .

[4]  A. Seif,et al.  Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. , 2013, The Journal of pediatrics.

[5]  V. Jurišić,et al.  Rituximab for treatment of autoimmune hemolytic anemia. , 2012, Indian pediatrics.

[6]  S. Yadav,et al.  Rituximab usage in children: a double edged sword. , 2012, Indian pediatrics.

[7]  M. Franchini,et al.  Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges , 2012, Seminars in Thrombosis & Hemostasis.

[8]  David T Selewski,et al.  Rituximab (Rituxan) , 2010, American Journal of Neuroradiology.

[9]  A. Iorio,et al.  Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review , 2010, Journal of thrombosis and haemostasis : JTH.

[10]  R. Keenan,et al.  Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort , 2009, Journal of thrombosis and haemostasis : JTH.

[11]  G. Lippi,et al.  Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  G. Zilleruelo,et al.  Rituximab therapy for juvenile-onset systemic lupus erythematosus , 2007, Pediatric Nephrology.

[13]  E. Santagostino,et al.  International workshop on immune tolerance induction: consensus recommendations 1 , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  M. Pescovitz.  Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  E. Neufeld,et al.  Rituximab for adolescents with haemophilia and high titre inhibitors , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  E. Tizzano,et al.  Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: An example of a significant decrease of treatment costs , 2006, Thrombosis and Haemostasis.

[17]  F. Tzortzatou-Stathopoulou,et al.  Rituximab in the treatment of high responding inhibitors in severe haemophilia A , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[19]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[20]  A. Mcelfresh.  What is hemophilia , 1974 .

[21]  J. Stockman.  Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors , 2013 .

[22]  M Alan Brookhart,et al.  Meta-analyses involving cross-over trials: methodological issues. , 2011, International journal of epidemiology.

[23]  A. Iorio,et al.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2006, The Cochrane database of systematic reviews.

[24]  S. Paisley,et al.  Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors. , 2004, The Cochrane database of systematic reviews.